Boston Scientific (BSX) expects the addressable market for its urology and pelvic health portfolio to grow from $3.5 billion in 2016 to $4.4 billion in 2020. This growth is expected to be driven by the company’s strong presence in the kidney stone treatment space and rapid expansion in developed and developing markets around the world.
Boston Scientific also expects to expand its presence in adjacent areas such as urologic cancer, overactive bladder, and urological visualization. These new opportunities are expected to increase Boston Scientific’s addressable market size by $2.6 billion, resulting in a total consolidated market opportunity of ~$7.0 billion for its urology and pelvic health business by 2020.
Boston Scientific is a leading medical device player in the kidney stone treatment space. The company expects LithoVue, launched in the United States in 2016, to become a standard of care. The company is targeting erectile dysfunction, benign prostatic hyperplasia, and incontinence in the men’s health area, and gynecological surgery and pelvic floor conditions in women’s health. In the next article, we’ll discuss growth prospects for Boston Scientific’s urology and pelvic health business in greater detail.